Madison Asset Management LLC Trims Position in Medpace Holdings, Inc. $MEDP

Madison Asset Management LLC lowered its position in shares of Medpace Holdings, Inc. (NASDAQ:MEDP) by 5.6% during the first quarter, Holdings Channel reports. The fund owned 262,293 shares of the company’s stock after selling 15,464 shares during the quarter. Medpace makes up approximately 1.6% of Madison Asset Management LLC’s investment portfolio, making the stock its 12th biggest position. Madison Asset Management LLC’s holdings in Medpace were worth $125,950,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Geneos Wealth Management Inc. lifted its stake in shares of Medpace by 64.9% during the 1st quarter. Geneos Wealth Management Inc. now owns 94 shares of the company’s stock worth $29,000 after purchasing an additional 37 shares during the period. Steigerwald Gordon & Koch Inc. acquired a new stake in shares of Medpace during the fourth quarter worth $30,000. Elyxium Wealth LLC purchased a new stake in shares of Medpace in the fourth quarter valued at $30,000. Quarry LP purchased a new stake in shares of Medpace in the third quarter valued at $35,000. Finally, Bayban acquired a new position in Medpace in the fourth quarter valued at $44,000. 77.98% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several equities analysts recently weighed in on MEDP shares. Mizuho increased their target price on Medpace from $495.00 to $586.00 and gave the stock an “outperform” rating in a research report on Monday, July 13th. Wall Street Zen downgraded shares of Medpace from a “buy” rating to a “hold” rating in a research note on Saturday, April 25th. BMO Capital Markets cut their price objective on shares of Medpace from $460.00 to $400.00 and set a “market perform” rating on the stock in a report on Friday, April 24th. Weiss Ratings reiterated a “hold (c+)” rating on shares of Medpace in a report on Thursday, July 2nd. Finally, Robert W. Baird reissued a “neutral” rating and issued a $547.00 target price (up from $477.00) on shares of Medpace in a research report on Wednesday, July 8th. Two investment analysts have rated the stock with a Buy rating, twelve have given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and an average price target of $469.50.

Insider Buying and Selling

In other Medpace news, General Counsel Stephen P. Ewald sold 16,349 shares of the company’s stock in a transaction dated Thursday, May 28th. The shares were sold at an average price of $450.00, for a total value of $7,357,050.00. Following the completion of the transaction, the general counsel directly owned 20,343 shares of the company’s stock, valued at $9,154,350. This represents a 44.56% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. 20.50% of the stock is owned by corporate insiders.

Medpace Stock Down 1.8%

NASDAQ MEDP opened at $527.93 on Tuesday. Medpace Holdings, Inc. has a fifty-two week low of $306.70 and a fifty-two week high of $628.92. The business has a 50 day moving average price of $480.31 and a two-hundred day moving average price of $493.94. The stock has a market cap of $15.08 billion, a PE ratio of 33.18, a P/E/G ratio of 2.69 and a beta of 1.15.

Medpace (NASDAQ:MEDP) last posted its quarterly earnings data on Wednesday, April 22nd. The company reported $4.28 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.74 by $0.54. The company had revenue of $706.60 million for the quarter, compared to analyst estimates of $697.82 million. Medpace had a net margin of 17.19% and a return on equity of 120.89%. The business’s quarterly revenue was up 26.5% on a year-over-year basis. During the same quarter last year, the firm posted $3.67 earnings per share. Medpace has set its FY 2026 guidance at 16.680-17.500 EPS. Sell-side analysts anticipate that Medpace Holdings, Inc. will post 17.04 EPS for the current fiscal year.

Medpace Profile

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.